Literature DB >> 33476175

Effect of tapentadol on experimental model of orofacial pain - a pilot study.

J Fricová1, H Lainczová, J Nedvídek, R Rokyta.   

Abstract

Acute orofacial pain is associated with significant disability and has a detrimental impact on quality of life. Although various origins of the pain in trigeminal territory can be identified an odontogenic pathology is the most common cause of acute orofacial pain in patients. Due to complex pathophysiology drugs with multitarget action might provide beneficial effect in pain management. The aim of the present study was to experimentally examine the anti-nociceptive effects of tapentadol, an opioid agonist and a norepinephrine reuptake inhibitor (MOR/NRI), in our animal model of orofacial pain. We tested the effect of tapentadol at gradual doses of 1, 2 and 5 mg/kg during thermal and mechanical stimulation in the trigeminal area of adult rats. We observed that tapentadol exhibits antinociceptive effect at dosages of 2 mg/kg and 5 mg/kg and only in association with mechanical stimulation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33476175      PMCID: PMC8603710          DOI: 10.33549/physiolres.934603

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  8 in total

1.  Thermal antinociception after buccal administration of a high-concentration formulation of buprenorphine (Simbadol) at 0.24 mg kg-1 in conscious cats.

Authors:  Graeme M Doodnaught; Beatriz Monteiro; Daniel Edge; Paulo Vm Steagall
Journal:  Vet Anaesth Analg       Date:  2018-06-15       Impact factor: 1.648

2.  Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

Authors:  Ilona Steigerwald; Matthias Müller; Anthony Davies; Daniel Samper; Rainer Sabatowski; Ralf Baron; Sylvie Rozenberg; Anna Szczepanska-Szerej; Antonio Gatti; Hans G Kress
Journal:  Curr Med Res Opin       Date:  2012-05-09       Impact factor: 2.580

3.  The treatment of orofacial pain by using transcranial direct current stimulation.

Authors:  J Fricová; K Englerová; J Nedvídek; R Rokyta
Journal:  Physiol Res       Date:  2019-12-20       Impact factor: 1.881

4.  Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.

Authors:  Robert Buynak; Douglas Y Shapiro; Akiko Okamoto; Ilse Van Hove; Christine Rauschkolb; Achim Steup; Bernd Lange; Claudia Lange; Mila Etropolski
Journal:  Expert Opin Pharmacother       Date:  2010-08       Impact factor: 3.889

5.  Tapentadol in an Experimental Animal Model of Acute Orofacial Pain.

Authors:  Jitka Fricova; Richard Rokyta; Jan Nedvidek
Journal:  Neuro Endocrinol Lett       Date:  2019-02       Impact factor: 0.765

6.  Effects of tramadol hydrochloride on the thermal threshold in cats.

Authors:  Bruno H Pypendop; Kristine T Siao; Jan E Ilkiw
Journal:  Am J Vet Res       Date:  2009-12       Impact factor: 1.156

7.  (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Kögel; Klaus Schiene; Hagen-Heinrich Hennies; Werner Englberger; Michael Haurand; Ulrich Jahnel; Thomas I F H Cremers; Elmar Friderichs; Jean De Vry
Journal:  J Pharmacol Exp Ther       Date:  2007-07-26       Impact factor: 4.030

8.  Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.

Authors:  Lucy A Bee; Kirsty Bannister; Wahida Rahman; Anthony H Dickenson
Journal:  Pain       Date:  2010-11-05       Impact factor: 6.961

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.